AU2013200489B2 - Methods for use in modulating miR-122a - Google Patents
Methods for use in modulating miR-122aInfo
- Publication number
- AU2013200489B2 AU2013200489B2 AU2013200489A AU2013200489A AU2013200489B2 AU 2013200489 B2 AU2013200489 B2 AU 2013200489B2 AU 2013200489 A AU2013200489 A AU 2013200489A AU 2013200489 A AU2013200489 A AU 2013200489A AU 2013200489 B2 AU2013200489 B2 AU 2013200489B2
- Authority
- AU
- Australia
- Prior art keywords
- mir
- methods
- activity
- elevated serum
- oligomeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108091026501 miR-122a stem-loop Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 7
- 230000000694 effects Effects 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 210000005228 liver tissue Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
METHODS FOR USE IN MODULATING MIR-122A Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013200489A AU2013200489B2 (en) | 2005-08-29 | 2013-01-31 | Methods for use in modulating miR-122a |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60/712,211 | 2005-08-29 | ||
| US60/731,377 | 2005-10-28 | ||
| US60/771,592 | 2006-02-07 | ||
| AU2011254085A AU2011254085B2 (en) | 2005-08-29 | 2011-12-15 | Methods for use in modulating miR-122a |
| AU2013200489A AU2013200489B2 (en) | 2005-08-29 | 2013-01-31 | Methods for use in modulating miR-122a |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011254085A Division AU2011254085B2 (en) | 2005-08-29 | 2011-12-15 | Methods for use in modulating miR-122a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013200489A1 AU2013200489A1 (en) | 2013-02-21 |
| AU2013200489B2 true AU2013200489B2 (en) | 2015-09-17 |
Family
ID=47722591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013200489A Ceased AU2013200489B2 (en) | 2005-08-29 | 2013-01-31 | Methods for use in modulating miR-122a |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2013200489B2 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
-
2013
- 2013-01-31 AU AU2013200489A patent/AU2013200489B2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013200489A1 (en) | 2013-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007027775A3 (en) | Methods for use in modulating mir-122a | |
| WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
| WO2008073919A3 (en) | Mir-20 regulated genes and pathways as targets for therapeutic intervention | |
| WO2009046141A3 (en) | Antisense modulation of fibroblast growth factor receptor 4 expression | |
| MX2010009654A (en) | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders. | |
| WO2006078659A3 (en) | Stable prostaglandin-containing compositions | |
| WO2007144394A3 (en) | Pharmaceutical use of substituted piperidine carboxamides | |
| WO2008073920A3 (en) | Mir-21 regulated genes and pathways as targets for therapeutic intervention | |
| WO2008036741A3 (en) | Mir-200 regulated genes and pathways as targets for therapeutic intervention | |
| WO2006026485A3 (en) | Modulation of hif1-beta expression | |
| WO2009070805A3 (en) | Mir-124 regulated genes and pathways as targets for therapeutic intervention | |
| WO2008062276A3 (en) | Acetylene derivatives as stearoyl coa desaturase inhibitors | |
| WO2009010974A8 (en) | Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis | |
| WO2008085797A3 (en) | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION | |
| ATE529404T1 (en) | PHENOXYACETIC ACIDS AS PPAR-DELTA ACTIVATORS | |
| WO2009037542A3 (en) | Spirocyclic compounds as stearoyl coa desaturase inhibitors | |
| WO2010007482A3 (en) | Thiazole derivatives as stearoyl coa desaturase inhibitors | |
| WO2005071080A3 (en) | Modulation of glucocorticoid receptor expression | |
| WO2011031063A3 (en) | Composition for preventing or treating metabolic disorders, containing the anti-4-1bb antibody | |
| WO2007062380A3 (en) | Modulation of eif4e-bp2 expression | |
| WO2008036718A3 (en) | Mir-143 regulated genes and pathways as targets for therapeutic intervention | |
| EP1648910A4 (en) | ANTISENSE MODULATION OF THE EXPRESSION OF STEAROYL COA DESATURASE | |
| WO2012145520A3 (en) | Carbon monoxide releasing molecules and uses thereof | |
| WO2009102366A3 (en) | Expression of orphan gpr64 in inflammatory diseases | |
| WO2009027527A3 (en) | Rna antagonist compounds for the modulation of fabp4/ap2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |